Denis Schmidt

Denis Schmidt

Auto-generated profile, based on publicly available information

Denis Schmidt

Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, Biberach an der Riß 88400, Germany

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2011 in RNA Biology
Verified
Journal Article
Open access
MVMichael-Paul Vockenhuber
Michael-Paul Vockenhuber
CSCynthia M. Sharma
Cynthia M. Sharma
MSMichaela G. Statt
Michaela G. Statt
DSDenis Schmidt
Denis Schmidt
ZXZhenjiang Xu
Zhenjiang Xu
BSBeatrix Suess
Beatrix Suess
Streptomyces coelicolor is considered the model organism among Gram positive, GC rich bacteria. Its genome has been sequenced but little is known about the occurrence and distribution of small non-coding RNAs in this biotechnologically relevant organism. Using deep sequencing we analyzed the transcriptome at the end of exponential growth, which corresponds to the onset of secondary metabolism. We mapped 193 transcriptional start sites of mRNA genes and identified putative new and alternative open reading frames. We identified 63 non-coding RNAs including 29 cis encoded antisense RNAs, and confirmed expression for 11, most of them being growth-phase dependent. A comparison between the sequencing results and bioinformatic sRNA predictions using Dynalign and RNAz revealed only a small overlap between the different approaches.

5 December 2014 in ACS Chemical Biology
Verified
Journal Article
Closed access
DSDenis Schmidt
Denis Schmidt
VBViachaslau Bernat
Viachaslau Bernat
RBRegine Brox
Regine Brox
NTNuska Tschammer
Nuska Tschammer
PKPeter Kolb
Peter Kolb

22 October 2019 in ACS Chemical Biology
Verified
Journal Article
Closed access
BWBarbara Wienen-Schmidt
Barbara Wienen-Schmidt
DSDenis Schmidt
Denis Schmidt
HGHans-Dieter Gerber
Hans-Dieter Gerber
AHAndreas Heine
Andreas Heine
HGHolger Gohlke
Holger Gohlke
GKGerhard Klebe
Gerhard Klebe

26 January 2021 in Molecules
Verified
Journal Article
Open access
PDF file
DSDenis Schmidt
Denis Schmidt
MSMagdalena M. Scharf
Magdalena M. Scharf
DSDominique Sydow
Dominique Sydow
EAEva Aßmann
Eva Aßmann
MMMaria Martí-Solano
Maria Martí-Solano
PKPeter Kolb
Peter Kolb
While selective inhibition is one of the key assets for a small molecule drug, many diseases can only be tackled by simultaneous inhibition of several proteins. An example where achieving selectivity is especially challenging are ligands targeting human kinases. This difficulty arises from the high structural conservation of the kinase ATP binding sites, the area targeted by most inhibitors. We investigated the possibility to identify novel small molecule ligands with pre-defined binding profiles for a series of kinase targets and anti-targets by in silico docking. The candidate ligands originating from these calculations were assayed to determine their experimental binding profiles. Compared to previous studies, the acquired hit rates were low in this specific setup, which aimed at not only selecting multi-target kinase ligands, but also designing out binding to anti-targets. Specifically, only a single profiled substance could be verified as a sub-micromolar, dual-specific EGFR/ErbB2 ligand that indeed avoided its selected anti-target BRAF. We subsequently re-analyzed our target choice and in silico strategy based on these findings, with a particular emphasis on the hit rates that can be expected from a given target combination. To that end, we supplemented the structure-based docking calculations with bioinformatic considerations of binding pocket sequence and structure similarity as well as ligand-centric comparisons of kinases. Taken together, our results provide a multi-faceted picture of how pocket space can determine the success of docking in multi-target drug discovery efforts.

27 May 2026 in Molecular Pharmaceutics
Verified
Journal Article
Open access
CBChristina Brenner
Christina Brenner
YCYunhai Cui
Yunhai Cui
DSDenis Schmidt
Denis Schmidt
Johannes KirchmairJohannes Kirchmair
Johannes Kirchmair
LTLu Tan
Lu Tan
NBNina Braun
Nina Braun
Most Proteolysis-Targeting Chimeras (PROTACs) are beyond-Rule-of-Five compounds, and optimizing their ability to cross cell membranes is a central topic in PROTAC therapeutic research. In this study, we systematically investigate the performance and assay correlations of PROTAC cell permeability assays and the chemical space in which these assays provide reliable results. Our work builds on a comprehensive data set of 3271 PROTACs spanning diverse chemical and target spaces, providing unprecedented coverage of PROTAC cell permeability data. These compounds were measured in up to three different types of assays: the NanoBRET E3 ligase target engagement assay, the Caco-2 assay, and a P-glycoprotein (P-gp) efflux liability assay. We find a strong correlation between readouts from the NanoBRET E3 ligase target engagement assay (availability shift) and those from the Caco-2 assay (apparent intrinsic permeability, basolateral-to-apical permeability, and efflux ratio), while P-gp liability derived from the P-gp assay cannot easily be translated to the Caco-2 efflux ratio. In the process, we also investigate the impact of physicochemical properties included in the Rule-of-Five on the applicability of the assays. Based on these findings, we derive guidelines and data-driven recommendations for the use of cell permeability assays in PROTAC optimization. While this study focuses on PROTACs, some of the observations may be relevant to other modalities with beyond-Rule-of-Five physicochemical properties.

24 September 2013 in DMW - Deutsche Medizinische Wochenschrift
Verified
Journal Article
Closed access
DSD. Schmidt
D. Schmidt
PKPeter Kolb
Peter Kolb